Literature DB >> 24671798

Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis.

M Hoenigl1, J Prattes2, B Spiess3, J Wagner2, F Prueller4, R B Raggam5, V Posch2, W Duettmann5, K Hoenigl2, A Wölfler5, C Koidl6, W Buzina6, M Reinwald3, C R Thornton7, R Krause2, D Buchheidt8.   

Abstract

Galactomannan detection in bronchoalveolar lavage (BAL) fluid samples (GM test) is currently considered the gold standard test for diagnosing invasive pulmonary aspergillosis (IPA). The limitations, however, are the various turnaround times and availability of testing. We compared the performance of GM testing with that of conventional culture, an Aspergillus lateral-flow-device (LFD) test, a beta-d-glucan (BDG) test, and an Aspergillus PCR assay by using BAL fluid samples from immunocompromised patients. A total of 78 BAL fluid samples from 78 patients at risk for IPA (74 samples from Graz and 4 from Mannheim) collected between December 2012 and May 2013 at two university hospitals in Austria and Germany were included. Three patients had proven IPA, 14 probable IPA, and 17 possible IPA, and 44 patients had no IPA. The diagnostic accuracies of the different methods for probable/proven IPA were evaluated. The diagnostic odds ratios were the highest for the GM, PCR, and LFD tests. The sensitivities for the four methods (except culture) were between 70 and 88%. The combination of the GM (cutoff optical density index [ODI], >1.0) and LFD tests increased the sensitivity to 94%, while the combination of the GM test (>1.0) and PCR resulted in 100% sensitivity (specificity for probable/proven IPA, 95 to 98%). The performance of conventional culture was limited by low sensitivity, while that of the BDG test was limited by low specificity. We evaluated established and novel diagnostic methods for IPA and found that the Aspergillus PCR, LFD, and GM tests were the most useful methods for diagnosing the disease by using BAL fluid samples. In particular, the combination of the GM test and PCR or, if PCR is not available, the LFD test, allows for sensitive and specific diagnosis of IPA.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24671798      PMCID: PMC4042784          DOI: 10.1128/JCM.00467-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  53 in total

1.  Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy.

Authors:  Martin Hoenigl; Katharina Seeber; Christoph Koidl; Walter Buzina; Albert Wölfler; Wiebke Duettmann; Jasmin Wagner; Volker Strenger; Robert Krause
Journal:  Mycoses       Date:  2013-02-24       Impact factor: 4.377

2.  β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis.

Authors:  Drosos E Karageorgopoulos; Evridiki K Vouloumanou; Fotinie Ntziora; Argyris Michalopoulos; Petros I Rafailidis; Matthew E Falagas
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

3.  Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.

Authors:  Martin Hoenigl; Wiebke Duettmann; Reinhard B Raggam; Katharina Seeber; Katharina Troppan; Sonja Fruhwald; Florian Prueller; Jasmin Wagner; Thomas Valentin; Ines Zollner-Schwetz; Albert Wölfler; Robert Krause
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

4.  False positive galactomannan Platelia due to piperacillin-tazobactam.

Authors:  M P Gerlinger; P Rousselot; S Rigaudeau; C Billon; S Touratier; S Castaigne; O Eloy
Journal:  Med Mal Infect       Date:  2011-12-05       Impact factor: 2.152

5.  Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid.

Authors:  S Husain; C J Clancy; M H Nguyen; S Swartzentruber; H Leather; A M LeMonte; M M Durkin; K S Knox; C A Hage; C Bentsen; N Singh; J R Wingard; L J Wheat
Journal:  Clin Vaccine Immunol       Date:  2008-10-08

6.  Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive Aspergillosis enhances diagnostic capabilities.

Authors:  M Reinwald; B Spiess; W J Heinz; C P Heussel; H Bertz; O A Cornely; J Hahn; T Lehrnbecher; M Kiehl; H J Laws; H H Wolf; R Schwerdtfeger; B Schultheis; A Burchardt; M Klein; M Dürken; B Claus; F Schlegel; M Hummel; W-K Hofmann; D Buchheidt
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

7.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  Comparison of a novel Aspergillus lateral-flow device and the Platelia® galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation.

Authors:  J Held; T Schmidt; C R Thornton; E Kotter; H Bertz
Journal:  Infection       Date:  2013-05-10       Impact factor: 3.553

9.  European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.

Authors:  Martin Hoenigl; Volker Strenger; Walter Buzina; Thomas Valentin; Christoph Koidl; Albert Wölfler; Katharina Seeber; Angelika Valentin; Anna T Strohmeier; Ines Zollner-Schwetz; Reinhard B Raggam; Christian Urban; Cornelia Lass-Flörl; Werner Linkesch; Robert Krause
Journal:  J Antimicrob Chemother       Date:  2012-05-07       Impact factor: 5.790

10.  Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology.

Authors:  Christopher Thornton; Gemma Johnson; Samir Agrawal
Journal:  J Vis Exp       Date:  2012-03-22       Impact factor: 1.355

View more
  57 in total

1.  Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs.

Authors:  Laura Loughlin; Thomas P Hellyer; P Lewis White; Danny F McAuley; Andrew Conway Morris; Raquel B Posso; Malcolm D Richardson; David W Denning; A John Simpson; Ronan McMullan
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

Review 2.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

3.  Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad T Hedayati; Vahid Moqarabzadeh; Saham Ansari; Saeed Mahdavi Omran; Hossein Zarrinfar; Sasan Saber; Paul E Verweij; David W Denning; Seyedmojtaba Seyedmousavi
Journal:  J Med Microbiol       Date:  2017-07-12       Impact factor: 2.472

4.  Usefulness of Two Aspergillus PCR Assays and Aspergillus Galactomannan and β-d-Glucan Testing of Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis.

Authors:  Naohisa Urabe; Susumu Sakamoto; Go Sano; Junko Suzuki; Akira Hebisawa; Yasuhiko Nakamura; Kazuya Koyama; Yoshikazu Ishii; Kazuhiro Tateda; Sakae Homma
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

5.  Urine Galactomannan-to-Creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematological Malignancies.

Authors:  Frederike M J Reischies; Reinhard B Raggam; Juergen Prattes; Robert Krause; Susanne Eigl; Agnes List; Franz Quehenberger; Volker Strenger; Albert Wölfler; Martin Hoenigl
Journal:  J Clin Microbiol       Date:  2015-12-23       Impact factor: 5.948

6.  Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device.

Authors:  Toine Mercier; Alexander Schauwvlieghe; Elizabeth de Kort; Albert Dunbar; Marijke Reynders; Ellen Guldentops; Bart Rijnders; Paul E Verweij; Katrien Lagrou; Johan Maertens
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 7.  Recent developments in the management of invasive fungal infections in patients with oncohematological diseases.

Authors:  Markus Ruhnke; Stefan Schwartz
Journal:  Ther Adv Hematol       Date:  2016-07-01

Review 8.  Aspergillus fumigatus and Aspergillosis in 2019.

Authors:  Jean-Paul Latgé; Georgios Chamilos
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

9.  Rapid and Sensitive Detection of Azole-Resistant Aspergillus fumigatus by Tandem Repeat Loop-Mediated Isothermal Amplification.

Authors:  Ling-Shan Yu; Jesus Rodriguez-Manzano; Kenny Malpartida-Cardenas; Thomas Sewell; Oliver Bader; Darius Armstrong-James; Matthew C Fisher; Pantelis Georgiou
Journal:  J Mol Diagn       Date:  2018-12-04       Impact factor: 5.568

Review 10.  Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation.

Authors:  Alisha Y Young; Miguel M Leiva Juarez; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-05-31       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.